Wells Fargo Maintains a Hold Rating on Mallinckrodt (MNK)

By Carrie Williams

In a report released today, David Maris from Wells Fargo maintained a Hold rating on Mallinckrodt (MNKResearch Report). The company’s shares closed last Monday at $2.35, close to its 52-week low of $1.43.

According to TipRanks.com, Maris has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.5% and a 34.7% success rate. Maris covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Establishment Labs Holdings Inc, and Osmotica Pharmaceuticals Plc.

Currently, the analyst consensus on Mallinckrodt is a Hold with an average price target of $5.90.

See today’s analyst top recommended stocks >>

The company has a one-year high of $32.34 and a one-year low of $1.43. Currently, Mallinckrodt has an average volume of 8.6M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines.